A next-generation multimetal complex induces immunogenic cell death with distinct transcriptomic signatures.

Area of Science:

• Medicinal Chemistry
• Nanomedicine
• Cancer Biology

Background:

• Platinum-based chemotherapy, like oxaliplatin, is a cornerstone in cancer treatment.
• Gold complexes offer unique therapeutic potential, including anti-cancer and immunomodulatory effects.
• Gemcitabine is a widely used nucleoside analog chemotherapy drug.

Purpose of the Study:

• To develop a novel platinum(IV)-gold(I)-gemcitabine prodrug.
• To investigate the co-release of oxaliplatin, a gold N-heterocyclic carbene (NHC), and gemcitabine.
• To evaluate the prodrug's efficacy in terms of cytotoxicity, metal uptake, and immunogenic cell death.

Main Methods:

• Synthesis and characterization of the Pt(IV)-Au(I)-gemcitabine prodrug.
• In vitro cytotoxicity assays against cancer cell lines.
• Cellular uptake studies using ICP-MS.
• Assessment of immunogenic cell death markers.

Main Results:

• The synthesized prodrug successfully co-released oxaliplatin, a redox-active gold NHC, and gemcitabine upon intracellular reduction.
• The prodrug exhibited significantly improved cytotoxicity compared to its individual components.
• Enhanced cellular uptake of platinum and gold was observed.
• The prodrug effectively induced an in vitro immunogenic cell death response.

Conclusions:

• The Pt(IV)-Au(I)-gemcitabine prodrug is a promising multi-modal therapeutic agent.
• Co-delivery of platinum, gold, and gemcitabine enhances anti-cancer efficacy.
• The prodrug's ability to induce immunogenic cell death warrants further investigation for cancer immunotherapy.